Addition of eicosapentaenoic acid to maintenance anti-depressant therapy in diabetes patients with major depressive disorder: a double-blind, placebo-controlled pilot study

Submission date	Recruitment status No longer recruiting	Prospectively registered		
28/04/2006		☐ Protocol		
Registration date 28/04/2006	Overall study status Completed	Statistical analysis plan		
		[X] Results		
Last Edited	Condition category	Individual participant data		
27/02/2013	Mental and Behavioural Disorders			

Plain English summary of protocol

Not provided at time of registration

Study website

http://www.diabetespsychology.nl/abstracts/omega-3.htm

Contact information

Type(s)

Scientific

Contact name

Dr F. Pouwer

Contact details

VU University Medical Center Department of Medical Psychology Diabetes Psychology Research Group Van der Boechorststraat 7 Amsterdam Netherlands 1081 BT +31 (0)20 4449679 f.pouwer@vumc.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

DFN 2004.13.004

Study information

Scientific Title

Study objectives

Addition of eicosapentaenoic acid (1 g/day) to maintenance anti-depressant therapy in diabetes patients with major depression will be associated with a reduction of depression symptoms, compared to placebo (1 g grapeseed oils).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics approval received from the Medical Ethical Committee of the VU Medical Centre, Amsterdam on the 15th September (ref: METC 2005/137)

Study design

Randomised placebo-controlled double blind trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Major depressive disorder

Interventions

Two capsules containing eicosapentaenoic acid (total amount of 1 g/day) or placebo.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Eicosapentaenoic acid

Primary outcome measure

Depression

Secondary outcome measures

Glycaemic control

Overall study start date

01/04/2006

Completion date

01/04/2007

Eligibility

Key inclusion criteria

- 1. 18 75 years old
- 2. Having diabetes
- 3. Current diagnosis of major depressive disorder that is being treated with ongoing antidepressant medication
- 4. Signed informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

30

Key exclusion criteria

- 1. Psychotic features
- 2. History of (hypo)-mania
- 3. An average consumption of fish higher than two servings per week or current daily use of fish oil supplements
- 4. Active suicidal ideation or a history of suicide attempt

5. Allergy for fish or fish products

6. Pregnancy

Date of first enrolment

01/04/2006

Date of final enrolment

01/04/2007

Locations

Countries of recruitment

Netherlands

Study participating centre
VU University Medical Center

Amsterdam Netherlands 1081 BT

Sponsor information

Organisation

VU University Medical Center, EMGO-Institute (The Netherlands)

Sponsor details

Van der Boechorststraat 7 Amsterdam Netherlands 1081 BT +31 (0)20 4448180 emgo@vumc.nl

Sponsor type

University/education

ROR

https://ror.org/00q6h8f30

Funder(s)

Funder type

Industry

Funder Name

Dutch Diabetes Research Foundation (The Netherlands)

Alternative Name(s)

Dutch Diabetes Research Foundation

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Netherlands

Funder Name

Minami Nutrition Inc. (USA)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/01/2012		Yes	No